No bones about the cost effectiveness of zoledronic acid

Research has demonstrated the clinical efficacy and cost effectiveness of zoledronic acid for the prevention of bone events in patients being treated for several types of cancer, but there are still gaps in the evidence base. To help fill these gaps, two economic evaluations of zoledronic acid were presented at the recent 14th European Cancer Conference (ECCO 14) [Barcelona, Spain; September 2007] in the following settings: for the prevention of skeletal-related events in patients with bone metastases secondary to renal cell carcinoma, and for the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with early breast cancer.